NCT00668200 - Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast® | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions

Paget's Disease of the BoneHypocalcemia

Interventions

DRUG

Reclast (ZOL446, zoledronic acid)

"5 mg i.v. annually (real-life, physician prescribed)"

DIETARY_SUPPLEMENT

Calcium

1500 mg elemental calcium daily in divided doses (the divided doses were 2-3 times per day depending on the formulation)

DIETARY_SUPPLEMENT

Vitamin D

800 IU vitamin D daily, particularly in the immediate 2 weeks following zoledronic acid administration

Trial Locations (9)

Novartis Investigative Site, Gainesville

Novartis Investigative Site, Detroit

Novartis Investigative Site, Dallas

Novartis Investigative Site, Waco

Novartis Investigative Site, Phoenix

Novartis Investigative Site, Tucson

Novartis Investigative Site, Syracuse

Novartis Investigative Site, Providence

Novartis Investigative Site, Madison